Esperion Therapeutics (ESPR) Misses Q3 EPS by 18c

Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($0.16), $0.18 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $87.3 million versus the consensus estimate of $92.5 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• NVIDIA (NVDA) Reiterated at Overweight by Cantor Fitzgerald: 'Still a Top Pick'
• Needham Reiterates Buy Rating on Veeva Systems (VEEV)